Patent: 10,072,301
✉ Email this page to a colleague
Summary for Patent: 10,072,301
| Title: | Means and methods for molecular classification of breast cancer |
| Abstract: | The invention relates to a method of typing a sample from a breast cancer patient. More specifically, the invention relates to a method for classification of breast cancer according to the presence or absence of Estrogen Receptor (ER), Progesterone Receptor (PR) and Human Epidermal growth factor Receptor 2 (ERBB2; HER2). More specifically, the invention provides methods and means to classify breast cancer as ER positive, triple negative (ER.sup.-, PR.sup.- and HER2.sup.-) and HER2+. |
| Inventor(s): | Krijgsman; Oscar (Almere, NL), Roepman; Paul (Bilthoven, NL), Glas; Annuska Maria (Assendelft, NL) |
| Assignee: | Agendia N.V. (Amsterdam, NL) |
| Application Number: | 14/925,838 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,072,301
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2031-07-13 |
| Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2031-07-13 |
| Genentech, Inc. | HERCEPTIN HYLECTA | trastuzumab and hyaluronidase-oysk | Injection | 761106 | 02/28/2019 | ⤷ Try a Trial | 2031-07-13 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
